Table II.
Patient characteristics.
| Number (%) | |||
|---|---|---|---|
| Male/Female | 56 (74.7%) | 19 (25.3%) | |
| Asthma | 35 (46.7%) | ||
| AERD | 20 (26.7%) | ||
| Previous sinus surgery | 45 (60%) | ||
| Diabetes | 6 (8%) | ||
| Cardiovascular diseases | 27 (36%) | ||
| Chronic obstructive Pulmonary disease | 3 (4%) | ||
| Anti-coagulant therapy | 3 (4%) | ||
| Antiplatelet therapy | 10 (13.3%) | ||
| Hypereosinophilia Y/N/not tested | 18 (24%) | 20 (26.7%) | 37 (49.3%) |
| Preoperative NPS (Highest score of both nasal cavities) | 1 | 1 (1.33%) | |
| 2 | 0 | ||
| 3 | 7 (9.33%) | ||
| 4 | 67 (89.33%) | ||
| Number of previous ESS | 0 | 30 (40%) | |
| 1 | 17 (22.7%) | ||
| 2 | 16 (21.3%) | ||
| 3 | 4 (5.3%) | ||
| 4 | 3 (4%) | ||
| 5 | 4 (5.3%) | ||
| 6 or more | 1 (1.3%) | ||
| Yearly SCT (1 mg/kg): ≤ 2 week/year / > 2 week/year | 29 (38.7%) | 46 (61.3%) | |
AERD: Aspirin Exacerbated Respiratory Disease; NPS: Nasal Polyp Score; ESS: Endoscopic Sinus Surgery; SCT: Systemic Corticosteroid Therapy.